Following impressive third-quarter results that surpassed projections, Johnson & Johnson has increased its full-year sales forecast for 2025. The healthcare giant’s Innovative Medicine and MedTech divisions both experienced notable expansion, as evidenced by the 6.8% increase in overall sales to $24.0 billion. For the quarter, the company’s earnings per share (EPS) jumped 91.0% to $2.12, while adjusted EPS also showed a strong 15.7% increase to $2.80.
Broad-Based Growth Across Key Segments
Strong growth in both of Johnson & Johnson’s primary business segments propelled the company’s outstanding third-quarter performance. Sales for the company’s largest division, Innovative Medicine, increased 6.8% to $15.563 billion. Strong sales of important cancer treatments like DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE drove this expansion. Significant contributions were also made by the immunology portfolio, which included medications like TREMFYA and SIMPONI/SIMPONI ARIA, as well as the neuroscience treatment SPRAVATO.
Updated 2025 Financial Outlook
Johnson & Johnson has increased its projected reported sales for the entire year 2025 in response to the impressive third-quarter results. At the halfway point, the company anticipates sales of about $93.7 billion, a 5.7% increase. Compared to the prior guidance of $93.4 billion, this represents an increase. The company has reiterated its midpoint adjusted EPS guidance of $10.85 for the year.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Johnson & Johnson appears to be in a strong position for future growth based on its impressive third-quarter performance and the upward revision of its sales outlook. Strong financial results are being driven by strategic acquisitions and key products, suggesting that the company’s emphasis on innovation in both its pharmaceutical and medical technology businesses is paying off.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
